https://orcid.org/0000-0003-2864-1961
References
- Dasgupta N, Gelber AC, Racke F, et al. Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus. 2005;14(11):910–913.
- Lai GGY, Koo YX, Tao M, et al. Use of rituximab in combination with high-dose methotrexate in the treatment of primary central nervous system lymphoma in a mycophenolate mofetil treated patient with lupus nephritis. Acta Oncol. 2011;50(1):144–145.
- Finelli PF, Naik K, DiGiuseppe JA, et al. Primary lymphoma of CNS, mycophenolate mofetil and lupus. Lupus. 2006;15(12):886–888.
- Guillevin L, Pagnoux C, Seror R, et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) Cohort. Medicine (Baltimore). 2011;90(1):19–27.
- Hauptrock B, Hess G. Rituximab in the treatment of non-Hodgkin’s lymphoma. Biologics. 2008;2(4):619–633.
- Tsang HHL, Trendell-Smith NJ, Wu AKP, et al. Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus. Lupus. 2010;19(3):330–333.
- Svobodova B, Hruskova Z, Rysava R, et al. Brain diffuse large B-cell lymphoma in a systemic lupus erythematosus patient treated with immunosuppressive agents including mycophenolate mofetil. Lupus. 2011;20(13):1452–1454.
- Kitchin JES, Washenik K. Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses. J Am Acad Dermatol. 1997;37(3):5.
- Omiya R, Buteau C, Kobayashi H, et al. Inhibition of EBV-induced lymphoproliferation by CD4+ T cells specific for an MHC class II promiscuous epitope. J Immunol. 2002;169(4):2172–2179.
- Kleinschmidt-DeMasters BK, Damek DM, Lillehei KO, et al. Epstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications. J Neuropathol Exp Neurol. 2008;67(11):1103–1111.
- Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6:32.
- Sola-Valls N, Rodríguez C Ny, Arcal C, et al. Primary brain lymphomas after kidney transplantation: an under-recognized problem? J Nephrol. 2014;27(1):95–102.
- O’Neill BP, Vernino S, Dogan A, et al. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol. 2007;9(3):364–369.
- Snanoudj R, Durrbach A, Leblond V, et al. Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation. 2003;76(6):930–937.
- Grinyó J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010;90(12):1521–1527.